Vaccine

Vaxxas secures funding for clinical trials of nanopatch delivered vaccines

update: WHO says tech like Nanopatch can help get vaccines to the people that need them

Vaxxas raises $20m for nanopatch vaccine trials

By Gareth Macdonald

Vaccine patch firm Vaxxas has raised $20m (€17.7m) to fund clinical development of its pipeline of influenza, polio and bacterial infection vaccines.

University of Texas has spent seven years developing a nasal spray vaccine against Ebola

DISPATCHES FROM AAPS 2014

Ebola nasal vaccine under threat as funding runs dry

By Dan Stanton

Lack of funding is threatening development of a nasal spray vaccine shown to provide long-term protection for non-human primates against the Ebola virus, the lead researcher told this publication in an exclusive interview.

Japanese biotech adopts MES at recombinant flu vaccine plant

Japanese biotech adopts MES at recombinant flu vaccine plant

By Zachary Brennan

Japanese biotech company Unigen has implemented in only four months Werum's PAS-X Manufacturing Execution System (MES), which can help optimize production output at the world’s largest plant for the contract manufacturing of recombinant flu vaccines.

Biopharma companies race to develop Ebola vaccine

Biopharma companies race to develop Ebola vaccine

By Zachary Brennan

As the death toll from the world’s most expansive Ebola outbreak nears 1,000, multiple companies are stepping up efforts to bring antibodies and other vaccines to human trials, though none seem likely to be ready until 2015 at the earliest.